概括
一个使用常规血液检测的新模型预测了克罗恩病 (CD) 风险. 这种工具有助于早期诊断和区分CD与肠结核病 (ITB) 等疾病.
科学领域:
- 胃肠病学 胃肠病学
- 内部医学 内部医学
- 诊断医学 诊断医学 诊断医学
背景情况:
- 在区分克罗恩病 (CD) 与性结肠炎 (UC) 和肠结核病 (ITB) 等其他疾病时,诊断错误很常见.
- 一个高效,快速和简单的预测模型对于CD诊断中的临床应用至关重要.
- 目前的诊断方法可能具有侵入性和耗时性,需要更简单的替代方案.
研究的目的:
- 开发一种CD风险预测模型,使用五种常规实验室测试.
- 为CD风险评估创建一个早期预警系统和一个视觉名字仪.
- 为临床医生提供一个方便的工具来确定CD风险和差异诊断.
主要方法:
- 对包括CD,UC,非IBD疾病和健康对照在内的310例病例 (2020-2022) 的回顾性分析.
- 使用基于血液学指数的逻辑回归来构建风险预测模型:ESR,Hb,WBC,ALb和CH.
- 模型被评估为诊断准确性,并使用名录仪可视化.
主要成果:
- 在CD和非CD组之间观察到ESR,WBC和WBC/CH比率的显著差异 (p <0.05).
- 白血球/血细胞比率与CD发生有很强的相关性 (相关系数>0.4).
- 一个逻辑回归模型证明了CD预测的高诊断准确性 (AUC=0.86) 和CD与ITB的区别 (AUC=0.88).
结论:
- 通过使用五种常规的血液学指数,成功建立了一个新的CD风险预测模型.
- 该模型通过名录仪可视化,为CD提供了高诊断准确度,以及其与ITB的差异化.
- 这种工具可以帮助临床医生更好地管理CD并减少患者的痛苦.
更多相关视频
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
7.2K
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
47.6K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
198
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
357
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
357
Inflammatory Bowel Disease II: Crohn's Disease
298
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
298
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175
